NWBO - Northwest Biotherapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Northwest Biotherapeutics, Inc.

4800 Montgomery Lane
Suite 800
Bethesda, MD 20814
United States

Full Time Employees14

Key Executives

NameTitlePayExercisedYear Born
Ms. Linda F. Powers J.D.Chairperson, CEO, Pres & CFO502kN/A1956
Dr. Alton L. BoyntonFounder, Chief Scientific Officer, Sec. & Director325kN/A1945
Dr. Marnix L. Bosch M.B.A., Ph.D., MBAChief Technical Officer375kN/A1959
Mr. Leslie J. GoldmanSr. VP & Gen. Counsel375kN/A1945
Mr. David InnesVP of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It is developing DCVax-L, a product in Phase III clinical trials to treat Glioblastome multiforme, a brain cancer; and DCVax-Direct, a product in Phase I/II clinical trials to treat various types of inoperable solid tumor cancers. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Corporate Governance

Northwest Biotherapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.